Potential mechanisms underlying anxiety and depression in Parkinson's disease: Consequences of l-DOPA treatment
- 1 January 2011
- journal article
- review article
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 35 (3) , 556-564
Abstract
No abstract availableKeywords
This publication has 126 references indexed in Scilit:
- Cortical serotonin and norepinephrine denervation in parkinsonism: preferential loss of the beaded serotonin innervationEuropean Journal of Neuroscience, 2009
- Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's diseaseMovement Disorders, 2009
- The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's diseaseMovement Disorders, 2009
- The role of the dorsal raphe nucleus in the development, expression, and treatment ofL‐dopa‐induced dyskinesia in hemiparkinsonian ratsSynapse, 2009
- The neuropathological basis for depression in Parkinson's diseaseParkinsonism & Related Disorders, 2009
- Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injuryNeurobiology of Disease, 2008
- Frequency and correlates of co-morbid psychosis and depression in Parkinson's diseaseParkinsonism & Related Disorders, 2006
- Simultaneous determination of in vivo hydroxylation of tyrosine and tryptophan in rat striatum by microdialysis-HPLC: relationship between dopamine and serotonin biosynthesisJournal of Neural Transmission, 1993
- Destruction of norepinephrine terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice reduces locomotor activity induced by l-DOPANeuroscience Letters, 1991
- Plasma Dopamine Beta Hydroxylase (D.B.H.) activity in Parkinsonian patients under L-dopa, and 2-Bromo-alpha-ergocriptine loadingJournal of Neural Transmission, 1979